Piramal Pharma Limited has announced that it will bolster its Piramal Pharma Solutions contract development and manufacturing organization by acquiring peptide active pharmaceutical ingredient specialist Hemmo Pharmaceuticals “for an upfront consideration of INR7.75bn ($106m) and earn-outs linked to achievement of milestones.”
Noting that the acquisition, which is subject to customary regulatory closing conditions, would add peptide API development and manufacturing capabilities to the CDMO business – with peptide drugs “growing significantly in oncology and metabolic therapies” – Piramal said that as a result of the